Celgene to buy Juno Therapeutics for $9 billion |  | (Reuters) - Celgene Corp said on Monday it would pay about $9 billion in cash to acquire the rest of Juno Therapeutics Inc and gain access to Juno's experimental gene therapy to treat cancer. | |  | |  |  | |  |  | Related Video | |  | |  | |  |  |  | Related News | |  | |  | |  |  |  |  |  | Make sense of the market with highlights of valuable financial information and reports along with compelling investment insights. Register Today |  | |  |  |  | Get a jump on the day with our early morning summary of key news developments for the US markets, as well as global market news. Register Today |  | |  | » » MORE NEWSLETTERS |  | |